Association Between Left Ventricular Global Function Index and Outcomes in Patients With Dilated Cardiomyopathy

Tong Liu, Zhen Zhou, Kairui Bo, Yifeng Gao, Hui Wang, Rui Wang, Wei Liu, Sanshuai Chang, Yuanyuan Liu, Yuqing Sun, David Firmin, Guang Yang, Jianzeng Dong, Lei XuFrontiers in Cardiovascular Medicine 2021 · DOI

TL;DR

This study investigates the Left Ventricular Global Function Index (LVGFI) as a predictor of adverse outcomes in patients with Dilated Cardiomyopathy (DCM). They found that a higher LVGFI, measured by cardiac magnetic resonance imaging (CMR), is significantly associated with a reduced risk of major adverse cardiac events (MACEs), suggesting it's a valuable prognostic tool.

What Problem Does This Paper Address?

Heart failure (HF) due to dilated cardiomyopathy (DCM) is a significant clinical challenge, often leading to poor prognoses. While Left Ventricular Ejection Fraction (LVEF) is a standard measure of systolic function and a predictor of outcomes, it doesn't fully capture the complex interplay of LV volume, mass, and function. This limitation means LVEF may not provide a comprehensive picture of cardiac performance, especially in DCM where structural remodeling is prominent. The paper addresses the need for a more integrated measure of LV function and structure to better predict clinical outcomes in DCM patients. Specifically, it explores the utility of LVGFI, a metric derived from CMR that combines LV volume and mass with global systolic function, in this patient population.

Methods

The researchers conducted a prospective cohort study involving 334 patients with DCM who underwent cardiac magnetic resonance (CMR) imaging. They used CMR to assess the Left Ventricular Global Function Index (LVGFI), which was calculated by integrating LV volume and mass with global systolic function. The primary exposure variable was LVGFI, and the main outcome was a composite of major adverse cardiac events (MACEs), defined as cardiovascular death or heart transplantation.

Statistical analysis involved:

  • Multivariable modeling: To assess the association between LVGFI and MACEs while adjusting for potential confounding factors (e.g., age, sex, BMI, comorbidities, other CMR parameters).
  • Kaplan-Meier analysis: To compare event-free survival between groups stratified by an optimal LVGFI cutoff value.
  • Time-dependent ROC curves: Used to determine the optimal cutoff for LVGFI.
  • Subgroup analyses: To examine if the association between LVGFI and MACEs varied across different patient characteristics.

Datasets

The study utilized data from 334 patients with DCM who underwent CMR imaging at Beijing Anzhen Hospital between January 2015 and April 2020. This is a single-center dataset. No new benchmarks were introduced; the study focused on evaluating an existing metric (LVGFI) in a specific patient population.

Key Insights and Ideas

  • LVGFI as a holistic predictor: The study reinforces the idea that LVGFI, by integrating structural (volume, mass) and functional (systolic function) aspects of the left ventricle, offers a more comprehensive assessment of cardiac performance than LVEF alone.
  • DCM-specific prognostic value: While LVGFI has shown promise in other cardiac conditions, its specific role in DCM, a disease characterized by significant structural remodeling, was less clear. This study provides evidence for its independent prognostic value in this patient group.
  • Consistent findings across subgroups: The robustness of the LVGFI-outcome association was demonstrated across various subgroups, suggesting its broad applicability within the DCM population, regardless of factors like age, sex, or the presence of certain comorbidities.

Key Results

  • A total of 334 patients with DCM were included, with a mean age of 55 years.
  • The average CMR-LVGFI was 16.53%.
  • Over a median follow-up of 565 days, 43 patients experienced a MACE.
  • Patients with LVGFI below the optimal cutoff of 15.73% had a significantly higher cumulative incidence of MACEs (log-rank P = 0.0021).
  • Each 1 standard deviation (SD) increase in LVGFI was associated with a 38% reduction in MACE hazard (HR 0.62).
  • After multivariable adjustment for confounders, each 1 SD increase in LVGFI was associated with a 46% reduction in MACE hazard (HR 0.54, 95% CI 0.32-0.89).

Limitations and Future Work

The authors acknowledge several limitations:

  • Single-center study: The findings may not be generalizable to other populations due to the single-center nature of the study.
  • Limited sample size: While 334 patients is a reasonable number, a larger, multicenter cohort would strengthen the generalizability of the results.
  • Subjective cause of death determination: The physician's judgment was used to determine the cause of death, which could introduce subjective bias.
  • Missing data: Data for the BNP covariate was missing in a significant portion of participants (29.9%). While multiple imputations were used, this remains a potential limitation.

Future work could involve validating these findings in larger, diverse, and multicenter cohorts. Further research could also explore the incremental prognostic value of LVGFI compared to other established markers like LVEF in various cardiac conditions.

Summary updated

Abstract

<b>Purpose:</b> Left ventricular global function index (LVGFI) assessed using cardiac magnetic resonance (CMR) seems promising in the prediction of clinical outcomes. However, the role of the LVGFI is uncertain in patients with heart failure (HF) with dilated cardiomyopathy (DCM). To describe the association of LVGFI and outcomes in patients with DCM, it was hypothesized that LVGFI is associated with decreased major adverse cardiac events (MACEs) in patients with DCM. <b>Materials and Methods:</b> This prospective cohort study was conducted from January 2015 to April 2020 in consecutive patients with DCM who underwent CMR. The association between outcomes and LVGFI was assessed using a multivariable model adjusted with confounders. LVGFI was the primary exposure variable. The long-term outcome was a composite endpoint, including death or heart transplantation. <b>Results:</b> A total of 334 patients (mean age: 55 years) were included in this study. The average of CMR-LVGFI was 16.53%. Over a median follow-up of 565 days, 43 patients reached the composite endpoint. Kaplan-Meier analysis revealed that patients with LVGFI lower than the cutoff values (15.73%) had a higher estimated cumulative incidence of the endpoint compared to those with LVGFI higher than the cutoff values (<i>P</i> = 0.0021). The hazard of MACEs decreased by 38% for each 1 SD increase in LVGFI (hazard ratio 0.62[95%CI 0.43-0.91]) and after adjustment by 46% (HR 0.54 [95%CI 0.32-0.89]). The association was consistent across subgroup analyses. <b>Conclusion:</b> In this study, an increase in CMR-LVGFI was associated with decreasing the long-term risk of MACEs with DCM after adjustment for traditional confounders.
BibTeX
@inproceedings{liu2021association,
  author = {Tong Liu and Zhen Zhou and Kairui Bo and Yifeng Gao and Hui Wang and Rui Wang and Wei Liu and Sanshuai Chang and Yuanyuan Liu and Yuqing Sun and David Firmin and Guang Yang and Jianzeng Dong and Lei Xu},
  title = {{Association Between Left Ventricular Global Function Index and Outcomes in Patients With Dilated Cardiomyopathy}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2021},
  doi = {10.3389/fcvm.2021.751907},
}
Figure